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Abstract
HIV-associated neurological disorders (HAND) are estimated to affect 60% of the HIV infected population. HIV-encephalitis
(HIVE), the pathological correlate of the most severe form of HAND is often characterized by glial activation, cytokine/
chemokine dysregulation, and neuronal damage and loss. However, the severity of HIVE correlates better with glial
activation rather than viral load. One of the characteristic features of HIVE is the increased amount of the neurotoxic
chemokine, CXCL10. This chemokine can be released from astroglia activated with the pro-inflammatory cytokines IFN-c
and TNF-a, in conjunction with HIV-1 Tat, all of which are elevated in HIVE. In an effort to understand the pathogenesis of
HAND, this study was aimed at exploring the regulation of CXCL10 by cellular and viral factors during astrocyte activation.
Specifically, the data herein demonstrate that the combined actions of HIV-1 Tat and the pro-inflammatory cytokines, IFN-c
and TNF-a, result in the induction of CXCL10 at both the RNA and protein level. Furthermore, CXCL10 induction was found
to be regulated transcriptionally by the activation of the p38, Jnk, and Akt signaling pathways and their downstream
transcription factors, NF-kB and STAT-1a. Since CXCL10 levels are linked to disease severity, understanding its regulation
could aid in the development of therapeutic intervention strategies for HAND.
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Introduction
Despite the use of combinatorial anti-retroviral therapy (cART)
HIV-associated dementia (HAD), a neurological complication in
end stage AIDS, still afflicts 9–11% of the HIV infected population
[1,2,3]. Even more disturbing is the fact that HIV-associated
neurocognitive disorders (HAND), which includes HAD, Minor
Cognitive Motor Disorders (MCMD), and other HIV related
neuropsychiatric impairments, are estimated to affect almost 60%
of HIV-1 patients [4,5]. These patients are diagnosed by changes
in behavior, and cognitive and motor abnormalities [5]. HAD, the
most severe form of HIV-1 induced CNS impairment [6], is
clinically characterized by motor and behavioral dysfunction that
in the absence of therapy may lead to seizures, coma, and death
within six months of onset [3].
HIV-1 is capable of penetrating the brain shortly after initial
infection [1]. However, while cART is able to control the virus in
the periphery, the drugs have inferior penetration across the blood
brain barrier [7]. So while HIV-1 patients are living longer, they
now have to deal with the long term effects of having HIV in the
brain. With the increasing prevalence of HAND it is essential to
understand the cellular and molecular mechanisms by which HIV
exerts its detrimental effects on the CNS. However, since this virus
does not infect neurons, the mechanism of neuronal damage and
loss seen in HIVE, a pathological correlate of HAD, is not
completely understood [8,9]. Neuronal toxicity is thought to
occur, in part, through glial activation and the release of cytotoxic
chemokines/cytokines [8,9], a hallmark feature of HIVE.
Astrocytes are a type of glial cell in the brain capable of
releasing neurotoxic chemokines/cytokines after activation by
either infection or injury. CXCL10, one of the neurotoxic
chemokines released by stimulated astrocytes is up-regulated in
the brains and CSF of patients with HIVE and is known to be
positively correlated with disease progression [10,11,12]. Further-
more, two regulators of CXCL10 expression, IFN-c and TNF-a,
are pro-inflammatory cytokines that are elevated in the brains of
patients with HIVE and are also associated with neuropathogen-
esis [13,14,15,16].
Another positive regulator of CXCL10 induction is the HIV-1
protein, Tat [17,18,19]. While astrocytes are not productively
infected with HIV-1, the provirus in these cells is able to make the
early HIV-1 genes, Tat, Rev and Nef [12,19]. Tat is not only
expressed in astrocytes and other productively infected cells like
microglia, but it can also be released from these cells to activate
other neighboring cells. Kutsch et. al. (2000) has reported that
astrocytes activated with Tat have the ability to release CXCL10.
Thus, with the increased expression of Tat and the pro-
inflammatory cytokines IFN-c and TNF-a in brains of patients
with HIVE, there exists a perfect milieu for exaggerated induction
of CXCL10 and the corresponding neuronal damage.
Increased levels of CXCL10 can be damaging to neurons both
directly and indirectly [11,20,21]. CXCL10 has direct toxic effects
by initiating the activation of a calcium-dependent apoptotic
pathway in neurons [11,20]. Indirectly, CXCL10 has the ability to
create a chemotactic gradient between the brain and the
periphery, allowing T-cells to infiltrate the brain, a hallmark
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blood brain barrier, but increases local inflammation, which can
be damaging to the neurons.
While both cellular (IFN-c and TNF-a) and viral (Tat)
mediators are known to induce CXCL10, it remains unclear
how the interplay of these host and viral factors modulates
chemokine expression in astrocytes. The data herein demonstrates
the increased induction of CXCL10 at both the RNA and protein
level in astrocytes activated with HIV-1 Tat, IFN-c, and TNF-a.
The data also reveals that this increase is regulated transcription-
ally by the activation of the p38, Jnk, and Akt signaling pathways
and their downstream transcription factors, NF-kB and STAT-1a.
Since CXCL10 levels are linked to disease severity, understanding
its regulation could lead to therapeutic intervention strategies for
those suffering from HAND.
Materials and Methods
Astrocyte cell culture and treatments
Primary human astrocytes (cat# HA1800; ScienCell Research
Laboratories, Carlsbad, CA) were prepared as described by the
supplier. The human astrocytic cell lines, U-87 and A172 (ATCC;
American Type Culture Collection, Manassas, VA), were grown
as described previously [22]. The cells (triplicate or quadruplicate
wells) were treated for 6–12 hrs (U87/A172) or 24 hours (primary
astrocytes), with: 1) HIV-1 Tat (1–72), 2) a combination of the
cytokines IFN-c (50 ng/ml) and TNF-a (5 ng/ml) or 3) HIV-1 Tat
and the cytokines. Control treatments included heat inactivated
HIV-1 Tat and cells receiving no treatment. The concentration of
Tat in the cerebral spinal fluid (CSF) has been reported at 16 ng/
ml [23]. However the concentration of Tat in the brain is
unknown, though expected to be much higher than in the CSF
[24]. The Tat concentration utilized in this in vitro study is
generally accepted [25,26,27,28,29].
The following specific pharmacological inhibitors were used at
the final concentration specified: PI3-K Inhibitor LY294002, PLC
inhibitor U73122, JAK inhibitor I, JNK inhibitor II, P38 inhibitor
SB203580, (all at 10 mM, Calbiochem, Gibbstown, NJ), and NF-
kB inhibitor N-p-Tosyl-L-phenylalanine chloromethyl ketone
(TPCK) (2 mM, Sigma, St. Louis, MO) [30,31,32,33,34].
CXCL10 mRNA analysis
RNA was extracted from U-87 astrocytes that were either
untreated or treated with HIV-1 Tat and/or the cytokines IFN-c
and TNF-a using TRIzol reagent following the treatment periods
(Invitrogen Life Technologies). Quantitative analysis of CXCL10
mRNA was done by quantitative Real-Time PCR using the SYBR
Green detection method. RT2 PCR primer pair set for CXCL10
was obtained from SuperArray Bioscience and amplification of
CXCL10 from first strand cDNA was performed as described
earlier [35] using ABI Prism 7700 sequence detector. Data were
normalized using Ct values for the house-keeping gene hypoxan-
thine-guanine phosphoribosyl transferase (HPRT) in each sample.
To calculate relative amounts of CXCL10, the average Ct value of
the HPRT was subtracted from that for each target gene to provide
changes in Ct value. The fold change in gene expression (differences
in changes in Ct value) was then determined as log2 relative units.
Luciferase assay
To determine the effects of HIV-1 Tat, IFN-c, and TNF-a on
the transcriptional regulation of CXCL10, astrocytes were
transfected with either the Luciferase reporter plasmid, TGL-
CXCL10 or a GFP plasmid (Amaxa Biosystems, using a
Nucleofector kit (Amaxa Biosystems) and allowed to recover
overnight [31]. The transfection efficiency of astrocytes was
around 30% as determined by analyzing the number of GFP
expressing cells in the GFP reporter plasmid transfected wells.
Following recovery the astrocytes transfected with the TGL-
CXCL10 plasmid were treated with HIV-1 Tat and the cytokines,
IFN-c and TNF-a. After 12 hours the cells were lysed and
Luciferase activity was measured using the Luciferase Reporter
Assay System (Promega) according to the manufacturer’s instruc-
tions. The resulting data was normalized by the protein content in
each sample. The data represents results obtained from three
independent experiments.
CXCL10 protein analysis by ELISA
Supernatants collected from primary human astrocytes or the
astrocytes cell lines U-87 and A172 that were either untreated or
treated with HIV-1 Tat and/or cytokines were examined for
secreted CXCL10 protein levels using a commercially available
CXCL10 ELISA kit (R&D Systems, Minneapolis, MN). The data
represents results obtained from three independent experiments.
Western Blot Analysis
Treated U-87 cells were lysed using the NE-PER Nuclear and
Cytoplasmic Extraction kits (Pierce, Rockford, IL). Equal amounts
of the corresponding proteins were electrophoresed in a sodium
dodecyl sulfate-polyacrylamide gel (12%) in reducing conditions
followed by transfer to PVDF membranes. The blots were blocked
with 5% non fat dry milk in phosphate buffered saline. Western
blots were then probed with antibodies recognizing the phosphor-
ylated forms of Jnk, Akt, p38, (Cell Signaling, Danvers, MA 1:200),
STAT1-a (Cell Signaling, 1:500), NF-kB p65 (Cell Signaling,
1:1000), and b-actin (Sigma, St. Louis, MO,1:4000) The
secondary antibodies were alkaline phosphatase conjugated to
goat anti mouse/rabbit IgG (1:5000). Signals were detected by
chemiluminescence (CDP-star; Tropix, Bedford, MA).
Statistical Analysis
All of the statistical analyses were performed by using a one-tail,
independent, Student’s t-test. The results were judged as
statistically significant at p values#0.05.
Results
Up-regulation of CXCL10 mRNA in astrocytes treated
with Tat, IFN-c and TNF-a
It has been previously shown that HIV-1 in conjunction with the
pro-inflammatory cytokines IFN-c and TNF-a can induce expres-
sion of CXCL10 in astrocytes [36]. In this study we wanted to
dissect the contribution of HIV-1 Tat in this phenomenon. U-87
astrocytes treated with either the cytokines alone or with Tat plus
the cytokines show a significant increase in CXCL10 mRNA as
early asthreehoursbyReal TimePCR(Fig.1A).While Tatbyitself
did not induce CXCL10 mRNA transcription, when combined
with IFN-c and TNF-a, it was capable of eliciting an increase in
CXCL10 mRNA. As shown in Figure 1, cells treated with both Tat
and the cytokines for just 6 hours demonstrated an almost 4000 fold
increaseinCXCL10mRNAascompared withthecellstreatedwith
the cytokines alone, thus underscoring the role of HIV-1 Tat in
potentiating the transcriptional regulation of CXCL10.
To confirm the role of Tat in the transcriptional regulation of
CXCL10, we performed luciferase reporter assays utilizing the
TGL-CXCL10 plasmid [31]. Briefly, U-87 cells were transfected
with a TGL-CXCL10 plasmid followed by a 12 hour treatment
with HIV-1 Tat and the cytokines, IFN-c and TNF-a. There was
a significant increase in luciferase expression in the cells exposed to
Tat,Cytokines Increase CXCL10
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the cytokines alone, thereby confirming a role for Tat in the
transcription of CXCL10 (Fig. 1B). Furthermore, when the U-87
astrocytes were transfected with the TGL-CXCL10 plasmid
containing a mutated IFN-stimulated response element (ISRE)
or a mutated kB binding site followed by treatment with Tat plus
the cytokines, there was little to no luciferase detected above
negative control levels. These data thus suggest that Tat in
combination with the cytokines can strongly activate the CXCL10
gene, and this activation is highly dependent on the occupancy of
the two key regulatory sequences, ISRE and kB.
CXCL10 protein expression is increased in the presence
of Tat and the cytokines
To confirm that the increase in CXCL10 RNA correlated with
an increase in CXCL10 protein, supernatants from U-87
astrocytes, A172 astrocytes, and primary human astrocytes were
collected and analyzed for CXCL10 expression using an ELISA
assay. As shown in Figure 2 and similar to the mRNA study, in
both the astrocyte cell lines, Tat by itself was unable to induce
CXCL10 expression. Similarly to the RNA studies, Tat in
combination with IFN-c and TNF-a, exerted a 2 fold increase
in CXCL10 protein levels over that of levels from cells treated with
only the cytokine mix. This phenomenon was confirmed in
primary human astrocytes and, similar to findings in cell lines, Tat
in conjunction with the cytokines resulted in a 2 fold increase in
CXCL10 expression over that of the cytokines by themselves.
Similar findings in both the cell lines as well as in primary human
astrocytes lend credence to the important role of Tat in
potentiating cytokine-mediated up-regulation of CXCL10.
Tat enhances activation of IFN-c/TNF-a signaling
pathways involved in CXCL10 regulation
Past studies have demonstrated that mitogen activated protein
kinase (MAPK) activation is critical in regulating inflammatory
responses such as cytokine/chemokine expression in response to
multiple stimuli [37,38,39,40]. We next sought to explore whether
HIV-1 Tat could potentiate the existing signaling pathways used
by IFN-c and TNF-a. U-87 astrocytes were treated with Tat
alone, the cytokines IFN-c and TNF-a alone, or a mixture of Tat
and the cytokines for 30 min. This time point was chosen based on
the time-dependent activation of p38, Jnk, and Akt in astrocytes
treated with Tat and the cytokines, where 30 min post-treatment
was the optimal time for enhanced phosphorylation as determined
by Western blot analysis (data not shown). As shown in Figure 3A
there was an increase in the activation of Jnk, p38, and Akt in cells
treated with the combination of Tat and cytokines compared with
cells exposed to either treatment alone. In each instance, as
expected each of the cytokine was able to induce phosphorylation
of each of the pathways. While Tat was able to mediate only a
modest activation of these pathways by itself, in the presence of
cytokines, it potentiated a robust activation of these pathways as
compared with the cytokines by themselves. These data demon-
strate the ability of Tat to enhance signaling pathways activated by
other pro-inflammatory molecules, thereby resulting in an
increased expression of the target gene CXCL10.
The roles of Jnk, p38, and Akt activation in CXCL10 induction
were further examined using a pharmacological approach. U-87
astrocytes were pretreated with either the Jnk II inhibitor, the P38
inhibitor SB203580, or the PI3-K Inhibitor LY294002, all at a
concentration of 10 mM, followed by stimulation of cells with Tat
and the cytokine mix for 6 hrs (Fig. 3E). Supernatants from treated
cells were collected and analyzed for CXCL10 content by ELISA.
Pre-treatment of the astrocytes with the Jnk, p38, and Akt
inhibitors followed by stimulation with Tat and cytokines resulted
in significant reduction of CXCL10, thus underscoring the role of
these signaling pathways in the induction of CXCL10.
Role of transcription factors NF-kB and STAT-1a in
induction of CXCL10
The transcription factors NF-kB and STAT-1a play key roles in
the induction of CXCL10 [5,41,42,43,44,45]. Both of these
transcription factors mediate CXCL10 regulation by binding to
specific regulatory sequences in the promoter region, the ISRE site
for STAT-1a and the kB1 and kB2 sites for NF-kB. Binding of
both NF-kB and STAT-1a is necessary for the synergistic increase
in CXCL10 mRNA/protein. IFN-c and TNF-a, through their
respective signaling pathways and subsequent activation of NF-kB
and STAT-1a, are known to synergistically increase CXCL10
Figure 1. Tat in combination with IFN-c and TNF-a increases
CXCL10 RNA. (A) Real Time PCR analysis showing a significant
increase in CXCL10 RNA in U-87 astrocytes treated with a combination
of Tat and cytokines. Cells were stimulated with either HIV-1 Tat alone,
the cytokines IFN-c and TNF-a, or Tat and the cytokines together for 6
hour followed by total cell lysis and RNA extraction. (B) Luciferase assay
demonstrating the ability of Tat in combination with the cytokines to
transcriptionally regulate the CXCL10 gene. The induction of CXCL10 is
dependent upon the binding of the ISRE and IkB regulatory sequences.
The data represents the mean6SD from three independent exper-
iments (*, p,0.05, ***, p,0.001).
doi:10.1371/journal.pone.0005709.g001
Tat,Cytokines Increase CXCL10
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cytokines, or Tat in conjunction with the cytokines for 60 min
followed by cell lysis and isolation of nuclear proteins. Nuclear
extracts were subsequently analyzed for p65-NF-kB and pSTAT-
1a content by Western Blot analysis.
As demonstrated in Figure 4A the ability of Tat to enhance
IFN-c/TNF-a signaling directly correlates with an increase in the
phosphorylation/activation of NF-kB and STAT-1a. To link the
increased activation of NF-kB and STAT-1a to CXCL10
regulation, U-87 cells were pretreated with the inhibitors specific
for NF-kB (TPCK at 2 mM) or JAK I (JAK I inhibitor at 10 mM)
followed by stimulation of cells with Tat and cytokine mix and
analyzed for CXCL10 by ELISA. As shown in Fig. 4D inhibition
of both NF-kB and STAT-1 resulted in a significant and
remarkable reduction in CXCL10 expression in astrocytes,
thereby confirming the role of these factors in viral and
cytokine-mediated synergistic induction of CXCL10.
Discussion
Up-regulated expression of chemokines in the brain has been
recognized as an important correlate of various neurodegenerative
diseases and related neuroinflammation. Chemokines and their
receptors are expressed by a wide variety of cells, including those
intrinsic to the CNS. These proteins can regulate inflammatory
responses by recruiting lymphocytes and monocytes/macrophages
to areas of inflammation within the brain contributing to the
injury and eventual loss of neurons [46,47]. Cerebral expression of
various chemokines and their receptors is increased in HIVE.
CXCL10 was first identified as an early response gene induced
after IFN-c treatment in a variety of cells [48,49]. Interactions of
soluble host factors, such as those between IFN-c and TNF-a,
have been shown to synergistically induce the expression of this
chemokine [42]. In addition to its induction by host factors,
CXCL10 can also be induced independently by the HIV-1 viral
protein Tat [12,19,50].
Increased levels of CXCL10 have been detected in the CSF and
plasma of individuals with HIV-1 infection [10]. Additionally,
brain tissue derived from patients with HAD also reveal increased
expression of mRNA for CXCL10 and this expression can be
localized to astrocytes [12,51]. Levels of this neurotoxic chemokine
are positively correlated with HAD disease progression [10].
Additionally, up-regulated expression of CXCL10 and its
neurotoxic role has also been previously demonstrated in SHIV-
infected macaque brains with lentiviral lesions [11,20].
In the current study we sought to explore the regulation of
CXCL10 in human astrocytes stimulated with a mixture of IFN-c,
TNF-a, and HIV-1 Tat. The rationale for using three different
stimulants was based on the premise that several host immune and
viral factors have the potential to interact during HAD, resulting
in neuronal damage and loss. The pro-inflammatory cytokine
TNF-a was chosen because it is a key cytokine produced by
activated astrocytes and microglia in response to HIV-1 [13,16].
Levels of this cytokine are also known to positively correlate with
HAD pathogenesis [13,14,15,16,52,53]. Furthermore, TNF-a has
the ability of not only inducing CXCL10 expression by itself
[16,54], but also synergistically with various other host factors,
such as IFN-c, thus increasing the toxicity and inflammation in the
surrounding milieu [13,16,42,45,55,56].
One of the well-studied host factors that has been shown to co-
operatively interact with TNF-a to induce CXCL10 is the pro-
inflammatory cytokine IFN-c [42,45]. Therefore IFN-c was also
chosen as an additional stimulant in the present study. IFN-c is a
known inducer for the expression CXCL10 in several cell types,
including astrocytes [42,48,49]. Additionally, IFN-c has been
shown to be markedly increased in CNS tissues during HIV-1
infection in the brain and has been implicated in the pathophys-
iology of HAD [57].
HIV-1 in combination with IFN-c and TNF-a has been shown
to synergistically up-regulate CXCL10 expression in human
astrocytes. However, which viral protein contributes to this effect
Figure 2. Tat in combination with IFN-c and TNF-a increases
CXCL10 protein. Increased CXCL10 protein expression in (A) primary
human astrocytes or (B) U-87 and A172 astrocytes cell lines treated
with HIV-1 Tat alone, the cytokines IFN-c and TNF-a, or Tat and the
cytokines together for 24 and 12 hours respectively. Both primary and
cell line astrocytes showed a significant increase in CXCL10 protein
levels in the cells treated with HIV-1 Tat and the cytokines, than with
either treatment alone. Treatment of U-87 and A172 cells with heat
inactivated (HI) Tat in conjunction with the cytokines did not lead to an
increase in CXCL10 protein levels compared with cells treated with the
cytokines alone. The data represents the mean6SD from three
independent experiments (**, p,0.01, ***, p,0.001).
doi:10.1371/journal.pone.0005709.g002
Tat,Cytokines Increase CXCL10
PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5709Figure 3. The p38, Jnk, and Akt signaling pathways mediate CXCL10 induction in stimulated U-87 astrocytes. A) Western Blot analysis
of cytosolic lysates collected from cells untreated, HIV-1 Tat treated, IFN-c and TNF-a treated, or treated with Tat in combination with the cytokines
for 30 min. The blots were probed with antibodies against phospho-p38, phospho-Jnk, and phosphor-Akt. An antibody against b-actin was used to
reprobe the blots for normalization. B), C) and D) Densitometric scans illustrating the ratio of phospho-p38, Jnk, and Akt to b-actin levels. E)
Activation of these pathways was shown to be involved in the increased expression of CXCL10 through inhibition of the p38 pathway by SB203580,
the Jnk pathway by Jnk II inhibitor, and the Akt pathway by LY294002. Inhibition of the PLC-c pathway by U73122 had no effect on CXCL10 protein
levels. The data represents the mean6SD from three independent experiments (*, p,0.05, **, p,0.01, ***, p,0.001).
doi:10.1371/journal.pone.0005709.g003
Tat,Cytokines Increase CXCL10
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known viral toxins involved in cytokine-mediated induction of
CXCL10, we initially examined the effects of HIV-1 Nef, the
envelope protein gp120, and Tat in conjunction with the cytokine
mix for their ability to up-regulate CXCL10 in U-87 astrocytes.
The rationale for selecting these viral toxins stems from their
expression in astrocytes and their ability to activate astrocytes
[12,19,50]. Since HIV-1 Tat (Fig. 2A) but not gp120 or Nef (data
not shown) demonstrated the most significant increase with the
cytokines in inducing both CXCL10 RNA and protein (Figs 1A
and 2A and B), we used HIV-1 Tat for our further studies.
Increased induction of CXCL10 RNA in astrocytes was
mediated via transcriptional regulation as demonstrated by
transfection of promoter constructs linked to luciferase reporter
gene. Using these assays it was demonstrated that combinatorial
treatment of astrocytes with the viral and host factors resulted in
increased transcription of the luciferase gene. Promoter constructs
with mutations in the ISRE (STAT-1a) binding site or IkB (NF-
kB) binding sites, the two major regulatory sequences in the
CXCL10 promoter [44,45,58], however, resulted in abrogation of
luciferase expression, thus underscoring the role of each of these
binding sites in the induction of CXCL10.
Figure 4. STAT-1a and NF-kB play a role in the increased induction of CXCL10 by HIV-1 Tat and the cytokines in U-87 astrocytes. A)
Western Blot analysis of nuclear lysates collected from cells untreated, HIV-1 Tat treated, IFN-c and TNF-a treated, or treated with Tat in combination
with the cytokines for 60 min. The blots were probed with antibodies against phospho-NF-kB p65 and phospho-STAT-1a. Antibodies against b-actin
were used to reprobe the blots for normalization. B), C) Densitometric scans illustrating the ratio of phospho-NF-kB p65 and phospho-STAT-1a to b-
actin levels. E) Activation of these transcription factors was shown to be involved in the increased expression of CXCL10 through inhibition of the NF-
kB by TPCK and the inhibition of the Jak/STAT pathway by a Jak I inhibitor. The data represents the mean6SD from three independent experiments
(***, p,0.001).
doi:10.1371/journal.pone.0005709.g004
Tat,Cytokines Increase CXCL10
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induction of CXCL10 in astrocytes suggested the involvement of
the Jnk, p38, and Akt pathways. These findings are in agreement
with the synergistic induction of CXCL10 mediated by intact
HIV-1 virus and the cytokine mix as reported earlier [36]. In each
of the three pathways (Jnk, p38, and Akt) there was modest
activation by Tat alone, and definitive activation by the cytokines
themselves, however, in the presence of all the three stimulants
there was a significant activation of each of these pathways, more
so than with either treatment alone. Confirmation of these
pathways using specific pharmacological inhibitors further indi-
cated their involvement in the regulation of CXCL10 expression.
Activation of the survival factor Akt [59,60,61] in the presence of
viral and host factors leads us to speculate that this could be a
mechanism by the virus to hijack the host machinery in order to
maintain a long term reservoir of the neurotoxic inflammatory
mediators, including CXCL10. It should be pointed out that
inhibition of one specific signaling pathway or transcription factor
never completely abrogated the expression of CXCL10, thus
indicating involvement of parallel signaling pathways and
transcription factors that could be working in unison.
All three pathways (Jnk, p38 and Akt) once activated, can in
turn activate the downstream transcription factor NF-kB, which
has two separate, yet vital binding sites on the CXCL10 promoter
[41]. Multiple studies have demonstrated that astrocytes activated
by HIV-1/viral proteins have increased nuclear translocation and
activation of the transcription factor NF-kB [36,62,63,64,65,66],
which, in turn, can regulate CXCL10 expression. In the present
study we demonstrate that exposure of astrocytes to Tat and the
cytokines results in increased activation and nuclear translocation
of the p65 subunit of NF-kB compared with cells treated with
either the viral or cellular stimuli. Since Jnk, p38, and Akt all have
the ability to activate NF-kB, their convergence on NF-kB could
lead to a dramatic increase in CXCL10 induction. In fact, when
NF-kB was pharmacologically inhibited, there was a significant
inhibition of CXCL10 expression.
While activation of NF-kB can be attributed to all the three
stimuli in astrocytes, STAT-1a activation is unique to IFN-c or
IFN-c plus TNF-a. Intriguingly, our data indicated significant
activation of STAT-1a in astrocytes treated with all three stimuli
and this was further confirmed using the JAK I specific inhibitor,
resulting in a dramatic decrease also in CXCL10 expression. Since
Figure 5. Schematic of the signaling pathways involved in the increased induction of CXCL10 in astrocytes stimulated with HIV-1
Tat in conjunction with IFN-c and TNF-a. The major signaling pathways activated include p38, Jnk, and Akt, which are able to converge on NF-
kB. The activation of NF-kB, along with the activation of STAT-1a, results in the transcription of CXCL10.
doi:10.1371/journal.pone.0005709.g005
Tat,Cytokines Increase CXCL10
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diffusing through the cell membrane, it should be noted that while
Tat activation of MAPK signaling pathways and transcription
factors has been reported [64], there is a paucity of information of
how Tat actually activates these proteins. Recent studies point to
the role of Tat-mediated activation of NADPH oxidase, a
membrane protein, as a key upstream player involved in the
activation of MAPK signaling pathways [67]. It is thus likely that
the activation of NADPH oxidase could explain the ability of Tat
to activate Jnk, p38, Akt and their downstream transcription
factors NF-kB and STAT-1a. Further studies exploring the role of
NADPH oxidase in this process are warranted.
In conclusion, we have provided evidence that HIV-1 Tat in
conjunction with the cytokines, IFN-c and TNF-a, is capable of
regulating CXCL10 expression in human astrocytes at both the
RNA and protein levels. This regulation is likely due to the
activation of the Jnk, p38, and Akt signaling pathways and
activation of their downstream transcription factors NF-kB and
STAT-1 as demonstrated in an overall schematic in Figure 5.
Given that the neuronal toxicity in HAD is thought to occur
through glial activation and the release of cytotoxic chemokines/
cytokines, dissecting the complex interplay between host factors
and viral proteins can lead to a better understanding of disease
pathogenesis. The ability of Tat to potentiate activation of
signaling pathways stimulated by IFN-c and TNF-a is an
ingenious approach by the virus to exploit the activated cells into
generating reservoirs of pro-inflammatory factors, such as
CXCL10. This in turn could aid in perpetuating activation,
infection, and destruction of several other cell types in the CNS.
Since excessive amounts of CXCL10 can be neurotoxic, our
findings lend further credence to the role of CXCL10 in
progression of AIDS-associated dementia. The consequences of
CXCL10 over expression not only include enhanced influx of
inflammatory cells into the CNS, but also amplification of
neuronal dysfunction/death in end-stage HAD. Since CXCL10
levels are linked to disease severity, understanding its regulation
could aid in the development of therapeutic intervention strategies
for HAND.
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